Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 3,501–3,600 of 10,906
Discovery of highly potent SARS-CoV-2 Mpro inhibitors based on benzoisothiazolone scaffold
Chen, W., Feng, B., Han, S., Wang, P., Chen, W., Zang, Y., Li, J. X., & Hu, Y. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128526 · Cited by 22
Self-citationAdvances of nanomaterials‐based strategies for fighting against COVID‐19
Zeng, C., Hou, X., Bohmer, M., & Dong, Y. (2021) · View · doi:10.1002/viw.20200180 · Cited by 21
Khawaja, F., Papanicolaou, G. A., Dadwal, S., Pergam, S. A., Wingard, J. R., Boghdadly, Z. E., Abidi, M. Z., Waghmare, A., Shahid, Z., Michaels, L., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.10.010 · Cited by 24
“Let me choose my COVID-19 vaccine”
Dal‐Ré, R., Stephens, R., & Sreeharan, N. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.01.030 · Cited by 20
Gutierrez-Alvarez, F. J., Honrubia, J. M., Sanz‐Bravo, A., González-Miranda, E., Fernández‐Delgado, R., Rejas, M. T., Zúñiga, S., Sola, I., & Enjuanes, L. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111075118 · Cited by 19
Nguyễn, V. H., Boileau, C., Bogdanov, A., Sredl, M., Bonafede, M., Ducruet, T., Chavers, S., Rosen, A., Martin, D., Buck, P. O., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad288 · Cited by 23
COVID-19 Vaccines in Patients with Maintenance Hemodialysis
Yen, C.-C., Lin, S., Chen, S., Chiu, Y., Chang, J., & Hwang, S. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080789 · Cited by 17
Iterative Screening of Vitamin E-Based Functional Lipid Nanoparticles for mRNA Delivery
Cui, K., Zhang, F., Shi, T., Zhao, S., Zhou, Y., Liu, X., Hu, Y. Y., Hu, Z., Kong, L., & Zhang, Z. (2025) · ACS Nano · doi:10.1021/acsnano.5c01378 · Cited by 20
Sáez‐Llorens, X., Lanata, C. F., Aranguren, E., Celis, C. R., Cornejo, R., DeAntonio, R., Ecker, L., Garrido, D., Gil, A. I., Gonzales, M., et al. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100189 · Cited by 22
Eberle, R. J., Gering, I., Tusche, M., Ostermann, P. N., Müller, L., Adams, O., Schaal, H., Olivier, D. S., do Amaral, M. S., Arni, R. K., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15050540 · Cited by 18
IgA vasculitis following COVID-19 vaccination
Nishimura, N., SHIOMICHI, Y., Takeuchi, S., Akamine, S., Yoneda, R., & Yoshizawa, S. (2022) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxac014 · Cited by 19
Nakhostin-Ansari, A., Zimet, G. D., Khonji, M. S., Aghajani, F., Teymourzadeh, A., Kazerooni, A. R., Pirayandeh, P., Aghajani, R., Safari, S., Khalaj, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10050670 · Cited by 24
Connolly, C. M., Koenig, D., Ravi, S. N., Azar, A., Kant, S., Dalal, M., Duchen, J., Seo, P., Antiochos, B., Paik, J. J., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220972 · Cited by 20
Quinn, K. L., Huang, A., Bell, C. M., Detsky, A. S., Lapointe‐Shaw, L., Rosella, L. C., Urbach, D. R., Razak, F. A., & Verma, A. A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.47341 · Cited by 20
Kałucka, S., Kusideł, E., Głowacka, A., Oczoś, P., & Grzegorczyk-Karolak, I. (2022) · Vaccines · doi:10.3390/vaccines10030401 · Cited by 37
Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study
Andersson, N. W., Thiesson, E. M., Hansen, J. V., & Hviid, A. P. (2023) · BMJ · doi:10.1136/bmj-2023-075015 · Cited by 22
Risma, K. (2021) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001077 · Cited by 21
Chernyshev, M., Sakharkar, M., Connor, R. I., Dugan, H. L., Sheward, D. J., Rappazzo, C. G., Stålmarck, A., Forsell, M. N. E., Wright, P. F., Corcoran, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37972-1 · Cited by 17
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
Sahly, H. M. E., Baden, L. R., Essink, B. J., Montefiori, D. C., McDermont, A., Rupp, R. E., Lewis, M., Swaminathan, S., Griffin, C., Fragoso, V. G., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac188 · Cited by 23
Self-citationOnyeaghala, A., Anyiam, A., Husaini, D. C., Onyeaghala, E., & Obi, E. (2023) · Scientific African · doi:10.1016/j.sciaf.2023.e01627 · Cited by 17
Schnake-Mahl, A. S., O’Leary, G., Mullachery, P. H., Skinner, A., Kolker, J., Roux, A. V. D., Raifman, J., & Bilal, U. (2022) · Health Affairs · doi:10.1377/hlthaff.2022.00779 · Cited by 20
The Progress and Evolving Trends in Nucleic-Acid-Based Therapies
Liu, Y., Wang, C., Fu, X., & Ren, M. (2025) · Biomolecules · doi:10.3390/biom15030376 · Cited by 31
“Phase III clinical trial results showed a 94.1% prevention effectiveness and 100% prevention effectiveness against severe COVID-19 [220].”
InfluentialLokras, A. G., Chakravarty, A., Rades, T., Christensen, D., Franzyk, H., Thakur, A., & Foged, C. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122171 · Cited by 23
Ren, Z.-X., Nishimura, M., Tjan, L. H., Furukawa, K., Kurahashi, Y., Sutandhio, S., Aoki, K., Hasegawa, N., Arii, J., Uto, K., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266270 · Cited by 19
Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response
Mazunina, E. P., Gushchin, V. А., Kleymenov, D. A., Siniavin, A. E., Ei, B., Шмаров, М. М., Мукашева, Е. А., Bykonia, E. N., Kozlova, S. R., Evgrafova, E. A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1381508 · Cited by 26
Huang, T., Zhang, S., Dai, D.-F., Wang, B., Zhuang, L., Huang, H.-T., Wang, Z., Zhao, J.-S., Li, Q., Wu, S., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00129-7 · Cited by 19
Andreica, I., Blazquez‐Navarro, A., Sokolar, J., Anft, M., Kiltz, U., Pfaender, S., Blanco, E. V., Westhoff, T. H., Babel, N., Stervbo, U., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002293 · Cited by 18
Adam, S. E., Zou, M., Kim, S., Henry, B., Krajden, M., & Skowronski, D. M. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac178 · Cited by 18
Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines
Walter, E. B., Schlaudecker, E. P., Talaat, K. R., Rountree, W., Broder, K. R., Duffy, J., Grohskopf, L. A., Poniewierski, M. S., Spreng, R. L., Staat, M. A., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.43166 · Cited by 21
Yu, X., Liu, S., Cheng, Q., Lee, S. M., Wei, T., Zhang, D., Farbiak, L., Johnson, L. T., Wang, X., & Siegwart, D. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111914 · Cited by 21
Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant
Yang, W., Greene, S. K., Peterson, E. R., Li, W., Mathes, R. W., Graf, L. E., Lall, R., Hughes, S., Wang, J., & Fine, A. D. (2022) · Science Advances · doi:10.1126/sciadv.abm0300 · Cited by 20
Strilchuk, A. W., Hur, W. S., Batty, P. A., Sang, Y., Abrahams, S. R., Yong, A. S. M., Leung, J., Silva, L. M., Schroeder, J. A., Nesbitt, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adh0027 · Cited by 22
Zarabanda, D., Vukkadala, N., Phillips, K. M., Qian, Z. J., Mfuh, K. O., Hatter, M. J., Lee, I. T., Rao, V. K., Hwang, P. H., Domb, G., et al. (2021) · The Laryngoscope · doi:10.1002/lary.29935 · Cited by 20
Comorbidities and Susceptibility to COVID-19: A Generalized Gene Set Data Mining Approach
Beckman, M. F., Igba, C. K., Mougeot, J. C., & Mougeot, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081666 · Cited by 19
Engineering CaP-Pickering emulsion for enhanced mRNA cancer vaccines via dual DC and NK activations
Wu, S., Zhou, Y., Asakawa, N., Wen, M., Sun, Y., Ming, Y., Song, T., Chen, W., Ma, G., & Xia, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.051 · Cited by 19
Martin, D. E., Cadar, A. N., & Bartley, J. M. (2023) · Frontiers in Aging · doi:10.3389/fragi.2023.1272336 · Cited by 22
Idres, Y. M., Idris, A., & Gao, W. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01815-x · Cited by 28
“This is in vast contrast to the rapid testing of RNA-based vaccines for SARS-CoV-2 which only required the virus sequence and within 6 weeks, phase 1 studies for the Moderna vaccine [11] were under-way.”
Bozkurt, B., Das, S. R., Addison, D., Gupta, A., Jneid, H. M., Khan, S. S., Koromia, G. A., Kulkarni, P. A., LaPoint, K., Lewis, E. F., et al. (2022) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000111 · Cited by 24
Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2
Juang, Y.-P., Chou, Y.-T., Lin, R., Ma, H., Chao, T., Jan, J., Chang, S., & Liang, P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114295 · Cited by 21
Kang, H. S., Kim, J. E., Yoo, J. R., et al. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2021.0131 · Cited by 19
Fukihara, J., & Kondoh, Y. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.05.007 · Cited by 24
COVID-19 Vaccination Uptake and Hesitancy Among Current Tobacco Users
Krebs, N. M., D’Souza-Rushton, G. C., Bordner, C. R., Allen, S. I., Hobkirk, A. L., Foulds, J., & Yingst, J. M. (2021) · Tobacco Use Insights · doi:10.1177/1179173x211068027 · Cited by 22
Zhang, P., Falcone, S., Tsybovsky, Y., Singh, M., Gopan, V., Miao, H., Seo, Y., Rogers, D., Renzi, I., Lai, Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305896120 · Cited by 21
Antibody response to COVID-19 vaccination in patients with lymphoma
Narita, K., Nakaji, S., Tabata, R., Terao, T., Kuzume, A., Tsushima, T., Ikeda, D., Fukumoto, A., Miura, D., Takeuchi, M., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03305-z · Cited by 20
Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines
Hofman, K., Shenoy, G. N., Chak, V., & Balu‐Iyer, S. V. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1904977 · Cited by 20
SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis
Efe, C., Taşçılar, K., Gerussi, A., et al. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102906 · Cited by 19
Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines
Neto, A. R. D. S., de Carvalho, A. R. B., da Silva, M. D. F., Neta, M. M. R., Sena, I. V. D. O., Almeida, R. N., Filha, F. S. S. C., Silva, L. L. L. E., da Costa, G. R., Lira, I. M. D. S., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064796 · Cited by 21
Bellanti, J. A. (2021) · Allergy and Asthma Proceedings · doi:10.2500/aap.2021.42.210063 · Cited by 24
Comprehensive Evaluation of the Toxicity and Biosafety of Plasma Polymerized Nanoparticles
Michael, P. L., Lam, Y. T., Hung, J., et al. (2021) · Nanomaterials · doi:10.3390/nano11051176 · Cited by 19
Lau, H.-C., Passalacqua, I., Jung, J., Kwon, Y., Zocco, D., Park, S., & Oh, S. W. (2024) · Scientific Reports · doi:10.1038/s41598-023-50279-x · Cited by 21
Blom, J. M. C., Rivi, V., Tascedda, F., & Pani, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1570899 · Cited by 31
Stopping the misinformation: BNT162b2 COVID-19 vaccine has no negative effect on women’s fertilityPreprint
Safrai, M., Rottenstreich, A., Herzberg, S., Imbar, T., Reubinoff, B. E., & Ben‐Meir, A. (2021) · medRxiv · doi:10.1101/2021.05.30.21258079 · Cited by 20
Fraley, E., LeMaster, C., Khanal, S., Banerjee, D., Pastinen, T., Grundberg, E., Selvarangan, R., & Bradley, T. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab850 · Cited by 18
Sputnik V Protection from COVID-19 of HIV-Infected Individuals Under Art
Gushchin, V. А., Tsyganova, E. V., Ogarkova, D. A., Adgamov, R. R., Shcheblyakov, D. V., Glukhoedova, N. V., Zhilenkova, A. S., Kolotii, A. G., Zaitsev, R. D., Logunov, D. Y., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101360 · Cited by 21
Huang, W., Chiem, K., Martínez‐Sobrido, L., & Lovell, J. F. (2022) · Pathogens · doi:10.3390/pathogens11091035 · Cited by 22
Advancements in RNA-based therapies from bench to bedside
Singh, A., Tekade, M., Nagaraja, S., Bharti, A., & Tekade, R. K. (2026) · npj Drug Discovery. · doi:10.1038/s44386-025-00037-y · Cited by 33
In vivo endosomal escape assay identifies mechanisms for efficient hepatic LNP delivery
Jozić, A., Roux, C. L., Kim, J., Berchel, M., Sahel, D. K., Bodi, E., Palumbo, M., Vasudevan, A., Murthy, N. T. V., Eygeris, Y., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03022-6 · Cited by 36
Jergović, M., Uhrlaub, J. L., Watanabe, M., Bradshaw, C. M., White, L. M., LaFleur, B., Edwards, T., Sprissler, R. S., Worobey, M., Bhattacharya, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30617-9 · Cited by 22
A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study
Anscombe, C., Lissauer, S., Thole, H., Rylance, J., Dula, D., Menyere, M., Kutambe, B. M., van der Veer, C., Phiri, T., Banda, N. P. K., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-022-07941-y · Cited by 27
Adams, L. J., VanBlargan, L. A., Liu, Z., Gilchuk, P., Zhao, H., Chen, R. E., Raju, S., Chong, Z., Whitener, B. M., Shrihari, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101305 · Cited by 18
SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma
Itell, H. L., Weight, H., Fish, C. S., Logue, J. K., Franko, N., Wolf, C. R., McCulloch, D. J., Galloway, J., Matsen, F. A., IV, Chu, H. Y., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01298-21 · Cited by 21
Cheng, Y., Li, T., Zheng, Y., Xu, B., Bi, Y., Hu, Y., & Zhou, Y. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2064134 · Cited by 23
Hajra, A., Gupta, M., Ghosh, B., Ashish, K., Patel, N., Manek, G., Rai, D. A., Sreenivasan, J., Goel, A., Lavie, C. J., et al. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00511-8 · Cited by 20
Bates, S. M., Munson, M. J., Trovisco, V., Pereira, S. G. T., Miller, S. R., Sabirsh, A., Betts, C. J., Blenke, E. O., & Gay, N. J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114047 · Cited by 31
Ohtsuka, J., Imai, M., Fukumura, M., Maeda, M., Eguchi, A., Ono, R., Maemura, T., Ito, M., Yamayoshi, S., Kataoka, Y., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103379 · Cited by 20
Khaled, S. M., Petcu, C. G., Bader, L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3790446 · Cited by 19
Ma, M., Santosa, A., Fong, W., Chew, L., Low, A., Law, A., Poh, Y. J., Yeo, S., Leung, Y.-Y., Ng, V., et al. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102959 · Cited by 17
Vaccines for the Elderly and Vaccination Programs in Europe and the United States
Anastassopoulou, C. G., Ferous, S., Medić, S., Siafakas, N., Boufidou, F., Gioula, G., & Tsakris, A. (2024) · Vaccines · doi:10.3390/vaccines12060566 · Cited by 24
Medina-Magües, L. G., Mühe, J., Jasny, E., Medina-Magües, E. S., Roth, N., Lopera-Madrid, J., Salas-Quinchucua, C., Knuese, C., Petsch, B., & Osorio, J. E. (2023) · npj Vaccines · doi:10.1038/s41541-023-00629-7 · Cited by 19
Thurm, C., Reinhold, A., Borucki, K., Kahlfuß, S., Feist, E., Schreiber, J., Reinhold, D., & Schraven, B. L. (2022) · Vaccines · doi:10.3390/vaccines10020333 · Cited by 19
SARS-CoV-2–Specific Vaccine Candidates; the Contribution of Structural Vaccinology
Pack, S. M., & Peters, P. J. (2022) · Vaccines · doi:10.3390/vaccines10020236 · Cited by 20
Cao, M., Li, Y., Song, X., Lu, Z., Zhai, H., Qiu, H., & Sun, Y. (2025) · Journal of Virology · doi:10.1128/jvi.00997-25 · Cited by 28
“Two doses of the BNT162b2 (BioNTech) and mRNA-1273 (Moderna) vaccines provided 94.8% and 94.1% protection against COVID-19, respectively (17, 18).”
InfluentialSeparation of long-stranded RNAs by RP-HPLC using an octadecyl-based column with super-wide pores
Kuwayama, T., Ozaki, M., Shimotsuma, M., & Hirose, T. (2022) · Analytical Sciences · doi:10.1007/s44211-022-00253-w · Cited by 19
Najjar, M., Albuaini, S., Fadel, M., Mohsen, F., Najjar, G., Assaf, D., Aljbawi, A., & AlAwad, Y. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2241351 · Cited by 21
Oosterhuis, I., Scholl, J. H. G., van Puijenbroek, E., Kant, A. C., & van Hunsel, F. P. A. M. (2022) · Drug Safety · doi:10.1007/s40264-022-01253-5 · Cited by 20
Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis
Reyes‐Leiva, D., López-Contreras, J., Moga, E., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200002 · Cited by 19
Estimating Vaccine Efficacy Against Transmission via Effect on Viral Load
Kennedy‐Shaffer, L., Kahn, R. J., & Lipsitch, M. (2021) · Epidemiology · doi:10.1097/ede.0000000000001415 · Cited by 22
Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies
Vogt, A. S., Jörg, L., Martina, B. E. E., Krenger, P. S., Chang, X., Zeltiņš, A., Vogel, M. T., Mohsen, M. O., & Bachmann, M. F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864718 · Cited by 20
Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy
Inoue, S., Igarashi, A., Morikane, K., Hachiya, O., Watanabe, M., Kakehata, S., Sato, S., & Ueno, Y. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.11.007 · Cited by 20
Godói, I. P. D., Sarmento, T. T. R., Reis, E. A., Gargano, L. P., Godman, B., Acúrcio, F. D. A., Álvares-Teodoro, J., Guerra, A. A., & Ruas, C. M. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1931128 · Cited by 21
Calleri, A., Saracco, M., Pittaluga, F., Cavallo, R., Romagnoli, R., & Martini, S. (2021) · Liver Transplantation · doi:10.1002/lt.26312 · Cited by 19
Lee, V., Adham, M., Kridis, W. B., Bossi, P., Chen, M.-Y., Chitapanarux, I., Grégoire, V., Hao, S.-P., Ho, C., Ho, G., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00505-8 · Cited by 18
The Experience of Greece as a Model to Contain COVID-19 Infection Spread
Delinasios, G. J., Fragkou, P. C., GKIRMPA, A. M., Tsangaris, G. T., Hoffman, R. M., & Anagnostopoulos, A. K. (2021) · In Vivo · doi:10.21873/invivo.12380 · Cited by 22
Mise‐Omata, S., Ikeda, M., Takeshita, M., Uwamino, Y., Wakui, M., Arai, T., Yoshifuji, A., Murano, K., Siomi, H., Nakagawara, K., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200525 · Cited by 22
Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study
Campello, E., Bulato, C., Simion, C., Spiezia, L., Radu, C. M., Gavasso, S., Sartorello, F., Saggiorato, G., Zerbinati, P., Fadin, M., et al. (2022) · Thrombosis and Haemostasis · doi:10.1055/a-1788-5206 · Cited by 19
Discovery and development of COVID ‐19 vaccine from laboratory to clinic
Saravanan, V., Chagaleti, B. K., Narayanan, P. L., Anandan, V. B., Manoharan, H., Anjana, G. V., Peraman, R., Namasivayam, S. K. R., Kavisri, M., Arockiaraj, J., et al. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14383 · Cited by 22
SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
Chaouat, A. E., Achdout, H., Kol, I., Berhani, O., Roi, G., Vitner, E. B., Melamed, S., Politi, B., Zahavy, E., Brizić, I., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010175 · Cited by 22
Wang, C., Pan, Q., Chen, S., Zhang, Y., Xu, X., Yan, X., Guo, J., Chen, X., Li, B., Ganzorig, C., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c08376 · Cited by 25
The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA
Taina-González, L., & de la Fuente, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020460 · Cited by 28
The global mRNA vaccine patent landscape
Li, M., Ren, J., Si, X., Sun, Z., Wang, P., Zhang, X., Liu, K., & Wei, B. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2095837 · Cited by 21
Ishio, T., Tsukamoto, S., Yokoyama, E., Izumiyama, K., Saito, M., Muraki, H., Kobayashi, M., Mori, A., Morioka, M., & Kondo, T. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05204-7 · Cited by 22
mRNA-encoded Cas13 treatment of Influenza via site-specific degradation of genomic RNA
Chaves, L. C. S., Orr‐Burks, N., Vanover, D. A., Mosur, V. V., Hosking, S. R., K., P. K. E., Jeong, H., Jung, Y., Assumpção, J. A. F., Peck, H. E., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012345 · Cited by 21
Kontou, E., Ranellou, K., Zoulas, D., Bletsa, A., Rompola, E., Piperaki, E., Athanasiou, N., Ampelakiotou, K., Pratikaki, M. E., Stergiopoulou, C., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060576 · Cited by 20
Nayrac, M., Dubé, M., Sannier, G., Nicolas, A., Marchitto, L., Tastet, O., Tauzin, A., Brassard, N., Lima-Barbosa, R., Beaudoin-Bussières, G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111013 · Cited by 18
Therapeutic gene silencing of CKAP5 leads to lethality in genetically unstable cancer cells
Chatterjee, S., Naidu, G. S., Hazan‐Halevy, I., Grobe, H., Ezra, A., Sharma, P., Goldsmith, M., Ramishetti, S., Sprinzak, D., Zaidel‐Bar, R., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade4800 · Cited by 23
Kempf, W., Kettelhack, N., Kind, F., Courvoisier, S., Galambos, J., & Pfaltz, K. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17506 · Cited by 19
Advances in Lipid-Based Pulmonary Nanomedicine for The Management of Inflammatory Lung Disorders
Kumar, M., Jha, A., Bharti, K., Parmar, G., & Mishra, B. (2022) · Nanomedicine · doi:10.2217/nnm-2021-0389 · Cited by 20
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.